Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Selectins01:25

Selectins

4.7K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
4.7K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Proteoglycans01:05

Proteoglycans

5.1K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance.

International journal of molecular sciences·2023
Same author

Phenotypic and Genetic Factors Associated with Absence of Cardiomyopathy Symptoms in PLN:c.40_42delAGA Carriers.

Journal of cardiovascular translational research·2023
Same author

Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population.

European journal of internal medicine·2023
Same author

Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER.

JACC. Heart failure·2023
Same author

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.

JACC. Heart failure·2023
Same author

The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.

European heart journal·2023

Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K

ST2 and Galectin-3: Ready for Prime Time?

Wouter C Meijers1, A Rogier van der Velde1, Rudolf A de Boer1

  • 1University Medical Center Groningen, University of Groningen , The Netherlands.

EJIFCC
|September 30, 2016
PubMed
Summary

Soluble ST2 and galectin-3 show promise as heart failure (HF) biomarkers, offering additional prognostic value beyond NT-proBNP. Further prospective studies are needed to confirm their role in HF management algorithms.

Keywords:
ST2biomarkersgalectin-3heart failureprognosis

More Related Videos

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
11:21

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

4.2K
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
10:00

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

9.0K

Related Experiment Videos

Last Updated: Mar 14, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.3K
Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions
11:21

Bioinformatics Resources for the Study of Glycan-Mediated Protein Interactions

Published on: January 20, 2022

4.2K
Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy
10:00

Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy

Published on: November 8, 2016

9.0K

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Heart Failure Research

Background:

  • Heart failure (HF) diagnosis and prognosis rely on clinical models and biomarkers like NT-proBNP.
  • Emerging biomarkers, including soluble ST2 (ST2) and galectin-3, are under investigation for their role in HF.
  • The added prognostic utility of ST2 and galectin-3 beyond established markers requires comprehensive evaluation.

Purpose of the Study:

  • To conduct a comprehensive review of ST2 and galectin-3 as emerging biomarkers in chronic, acute, and incident heart failure.
  • To assess the additional prognostic value of ST2 and galectin-3 compared to clinical models and NT-proBNP in HF.
  • To explore the potential future role of these biomarkers in guiding HF therapy.

Main Methods:

  • Systematic literature review of studies investigating ST2 and galectin-3 in various HF contexts.
  • Analysis of prognostic data comparing biomarker combinations against established clinical predictors.
  • Synthesis of evidence regarding the incremental value of ST2 and galectin-3 in different HF populations.

Main Results:

  • Both ST2 and galectin-3 appear to provide incremental prognostic information in addition to clinical models and natriuretic peptides across HF types.
  • The combined use of multiple biomarkers, including ST2 and galectin-3, may offer future therapeutic guidance.
  • The currently observed additional prognostic value of ST2 and galectin-3 is noted to be limited.

Conclusions:

  • ST2 and galectin-3 demonstrate potential as valuable biomarkers in heart failure management.
  • Prospective validation studies are essential to confirm consistent findings and support clinical implementation.
  • Integration of ST2 and galectin-3 into HF management algorithms may be considered following robust prospective testing.